000890616 001__ 890616
000890616 005__ 20220930130307.0
000890616 0247_ $$2doi$$a10.1093/neuonc/noab013
000890616 0247_ $$2ISSN$$a1522-8517
000890616 0247_ $$2ISSN$$a1523-5866
000890616 0247_ $$2Handle$$a2128/27922
000890616 0247_ $$2altmetric$$aaltmetric:99418310
000890616 0247_ $$2pmid$$a33538838
000890616 0247_ $$2WOS$$aWOS:000704008200008
000890616 037__ $$aFZJ-2021-01076
000890616 041__ $$aEnglish
000890616 082__ $$a610
000890616 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author
000890616 245__ $$aContribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group
000890616 260__ $$aOxford$$bOxford Univ. Press$$c2021
000890616 3367_ $$2DRIVER$$aarticle
000890616 3367_ $$2DataCite$$aOutput Types/Journal article
000890616 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1623238060_15860
000890616 3367_ $$2BibTeX$$aARTICLE
000890616 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000890616 3367_ $$00$$2EndNote$$aJournal Article
000890616 520__ $$aThe management of patients with glioma usually requires multimodality treatment including surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for radiotherapy planning and follow-up after radiotherapy completion. In order to maximize the radiation dose to the tumor and to minimize toxic effects on the surrounding brain parenchyma, reliable identification of tumor extent and target volume delineation is crucial. The use of positron emission tomography (PET) for radiotherapy planning and monitoring in gliomas has gained considerable interest over the last several years, but Class I data are not yet available. Furthermore, PET has been used after radiotherapy for response assessment and to distinguish tumor progression from pseudoprogression or radiation necrosis. Here, the Response Assessment in Neuro-Oncology (RANO) working group provides a summary of the literature and recommendations for the use of PET imaging for radiotherapy of patients with glioma based on published studies, constituting levels 1-3 evidence according to the Oxford Centre for Evidence-based Medicine.
000890616 536__ $$0G:(DE-HGF)POF4-525$$a525 - Decoding Brain Organization and Dysfunction (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000890616 588__ $$aDataset connected to CrossRef
000890616 7001_ $$0P:(DE-HGF)0$$aNiyazi, Maximilian$$b1
000890616 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca L$$b2
000890616 7001_ $$0P:(DE-Juel1)173675$$aKocher, Martin$$b3
000890616 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b4
000890616 7001_ $$0P:(DE-HGF)0$$aLaw, Ian$$b5
000890616 7001_ $$0P:(DE-HGF)0$$aMinniti, Giuseppe$$b6
000890616 7001_ $$0P:(DE-HGF)0$$aKim, Michelle M$$b7
000890616 7001_ $$0P:(DE-HGF)0$$aTsien, Christina$$b8
000890616 7001_ $$0P:(DE-HGF)0$$aDhermain, Frederic$$b9
000890616 7001_ $$0P:(DE-HGF)0$$aSoffietti, Riccardo$$b10
000890616 7001_ $$0P:(DE-HGF)0$$aMehta, Minesh P$$b11
000890616 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b12
000890616 7001_ $$0P:(DE-HGF)0$$aTonn, Jörg-Christian$$b13
000890616 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noab013$$gp. noab013$$n6$$p881–893$$tNeuro-Oncology$$v23$$x1523-5866$$y2021
000890616 8564_ $$uhttps://juser.fz-juelich.de/record/890616/files/Invoice-E14341918.pdf
000890616 8564_ $$uhttps://juser.fz-juelich.de/record/890616/files/noab013.pdf
000890616 8564_ $$uhttps://juser.fz-juelich.de/record/890616/files/Galldiks_2021_NeuroOncol_Contribution%20of%20PET%20imaigng%20to%20radiotherapy...post%20print.pdf$$yPublished on 2021-02-04. Available in OpenAccess from 2022-02-04.
000890616 8767_ $$8E14341918$$92021-02-14$$d2021-02-19$$eOther$$jZahlung erfolgt$$zBelegnr. 1200164129
000890616 8767_ $$8E14392711$$92021-03-17$$d2021-03-29$$eColour charges$$jZahlung erfolgt$$zBelegnr.1200165188 / 2021
000890616 909CO $$ooai:juser.fz-juelich.de:890616$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000890616 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
000890616 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)173675$$aForschungszentrum Jülich$$b3$$kFZJ
000890616 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b4$$kFZJ
000890616 9130_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000890616 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000890616 9141_ $$y2021
000890616 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000890616 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2018$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2018$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-32
000890616 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-08-32$$wger
000890616 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-32
000890616 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000890616 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000890616 980__ $$ajournal
000890616 980__ $$aVDB
000890616 980__ $$aUNRESTRICTED
000890616 980__ $$aI:(DE-Juel1)INM-3-20090406
000890616 980__ $$aI:(DE-Juel1)INM-4-20090406
000890616 980__ $$aAPC
000890616 9801_ $$aAPC
000890616 9801_ $$aFullTexts